Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/645"
| Predicate | Value (sorted: none) |
|---|
| rdf:type |
|
| rdf:type |
|
| rdfs:label |
|
| ?:Evidence_type |
|
| ?:Evidence_enzyme_system |
|
| dc:creator |
|
| dc:date |
|
| ?:content |
"Drugs that Inhibit Cytochrome P450 Isoenzymes
CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants. Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism and venlafaxine. However, although imipramine partially inhibited the CYP2D6-mediated metabolism of venlafaxine, resulting in higher plasma concentrations of venlafaxine and lower plasma concentrations of ODV, the total concentration of active compounds (venlafaxine plus ODV) was not affected. Additionally, in a clinical study involving CYP2D6-poor and -extensive metabolizers, the total concentration of active compounds (venlafaxine plus ODV), was similar in the two metabolizer groups. Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor."
|
| rdfs:seeAlso |
|
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ venlafaxine_is_not_substrate_of_cyp2d6, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1887 }
Context graph
